Clinical Trial Results:
A phase IA/II multicenter, dose-escalation study of oral AMN107 on a continuous daily dosing schedule in adult patients with Gleevec (imatinib)-resistant/intolerant CML in chronic or accelerated phase or blast crisis, relapsed/refractory Ph+ ALL or other hematologic malignancies
Summary
|
|
EudraCT number |
2004-001483-51 |
Trial protocol |
FI GB SE IT DK AT ES |
Global completion date |
20 Sep 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v2(current) |
This version publication date |
21 Oct 2021
|
First version publication date |
15 Feb 2017
|
Other versions |
v1 |
Version creation reason |
|
Summary report(s) |
CAMN107A2101.CTR.19Aug2016 Full results |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.